scholarly journals A Clinical Trial of Curative Accelerated Partial-Breast Irradiation for Stage I Breast Cancer using Carbon Ion Radiotherapy

2019 ◽  
Vol 105 (1) ◽  
pp. E24
Author(s):  
K. Karasawa ◽  
T. Omatsu ◽  
N. Okonogi ◽  
H. Murata ◽  
S. Fukuda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Stage I ◽  
Carbon Ion Radiotherapy ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Breast Irradiation ◽  
Carbon Ion

scholarly journals A Clinical Study of Curative Partial Breast Irradiation for Stage I Breast Cancer using Carbon ion Radiotherapy

2020 ◽  
Author(s):  
Kumiko Karasawa ◽  
Tokuhiko Omatsu ◽  
Shintaro Shiba ◽  
Daisuke Irie ◽  
Masaru Wakatsuki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Response ◽  
Stage I ◽  
Carbon Ion Radiotherapy ◽  
Partial Breast Irradiation ◽  
Eligibility Criteria ◽  
Dose Escalation Study ◽  
Carbon Ion ◽  
Time Required

Abstract Background and purpose: Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome up to May 2020.Materials and methods: Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy ([Relative Biological Efficacy (RBE)]). After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results: Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbon-ion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results.Conclusions: The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbon-ion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

scholarly journals EP-1175: Accelerated Partial Breast Irradiation using Carbon-iron Radiotherapy for stage I breast cancer

2016 ◽  
Vol 119 ◽  
pp. S559-S560
Author(s):  
K. Karasawa ◽  
T. Omastu ◽  
M. Wakatsuki ◽  
S. Shiba ◽  
S. Fukuda ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stage I ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Breast Irradiation ◽  
Carbon Iron

scholarly journals A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

2020 ◽  
Author(s):  
Kumiko Karasawa ◽  
Tokuhiko Omatsu ◽  
Shintaro Shiba ◽  
Daisuke Irie ◽  
Masaru Wakatsuki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Response ◽  
Stage I ◽  
Carbon Ion Radiotherapy ◽  
Partial Breast Irradiation ◽  
Eligibility Criteria ◽  
Dose Escalation Study ◽  
Carbon Ion ◽  
Time Required

Abstract Background and purpose: Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020.Materials and methods: Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy ([Relative Biological Efficacy (RBE)]). After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results: Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbon-ion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results.Conclusions: The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbon-ion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

scholarly journals A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation

2019 ◽  
Vol 60 (3) ◽  
pp. 342-347 ◽  
Author(s):  
Kumiko Karasawa ◽  
Tokuhiki Omatsu ◽  
Atsushi Arakawa ◽  
Naohito Yamamoto ◽  
Takashi Ishikawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Phase I ◽  
Phase I Clinical Trial ◽  
Stage I ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion ◽  
Pathological Evaluation

scholarly journals A clinical study of curative partial breast irradiation for stage I breast cancer using carbon ion radiotherapy

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Kumiko Karasawa ◽  
Tokuhiko Omatsu ◽  
Shintaro Shiba ◽  
Daisuke Irie ◽  
Masaru Wakatsuki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Complete Response ◽  
Stage I ◽  
Carbon Ion Radiotherapy ◽  
Partial Breast Irradiation ◽  
Eligibility Criteria ◽  
Dose Escalation Study ◽  
Carbon Ion ◽  
Time Required

Abstract Background and purpose Our institute initiated carbon ion radiotherapy research for patients with stage I breast cancer in April 2013. The purpose of this article is to evaluate the treatment outcome of cases treated outside clinical trial up to May 2020. Materials and methods Eligibility criteria of the patients were having untreated stage I breast cancer and being unsuitable for operation for physical or mental reasons. The irradiated volume was defined as the gross tumor including intraductal components. The dose escalation study was initially conducted four times a week for a total of 52.8 Gy [relative biological efficacy (RBE)]. After confirming that adverse effects were within acceptable range, the total dose was increased to 60.0 Gy (RBE). Results Between April 2013 and November 2015, 14 cases were treated. The median follow up period was 61 months. No adverse toxicities were observed except for grade 1 acute skin reaction in 10 cases. The time required from carbonion radiotherapy to tumor disappearance was 3 months in 1 case, 6 months in 3 cases, 12 months in 4 cases, and 24 months in 5 cases. The third case developed local recurrence 6 months after radiotherapy. Twelve patients with luminal subtype received 5-year endocrine therapy. Thirteen of 14 tumors have been maintaining complete response with excellent cosmetic results. Conclusions The time from carbon ion radiotherapy to tumor disappearance was longer than expected, but complete tumor disappearance was observed except for one high-grade case. With careful patient selection, carbonion radiotherapy in patients with stage I breast cancer is deemed effective and safe, and further research is recommended.

Five-day accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A report of 214 cases with up to 39 month follow-up.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12508-e12508
Author(s):  
Rufus J. Mark ◽  
Valerie Gorman ◽  
Michal Wolski ◽  
Steven McCullough
Keyword(s):  
Breast Cancer ◽  
Intensity Modulated Radiation Therapy ◽  
Target Volume ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Breast Irradiation ◽  
Skin Reactions ◽  
Cosmetic Results ◽  
Non Invasive

e12508 Background: Randomized trials in stage 0-II breast cancer have proven that APBI given via HDR implant in 5 days is equivalent to whole breast irradiation (WBI) given in 5-6 weeks in regard to breast tumor local recurrence (LR). However, complications have been significant. Recently APBI using non-invasive IMRT given in 5 fractions has been shown in another randomized trial with 10 year follow-up to be equivalent to WBI in 6 weeks, with respect to LR. IMRT was superior in regard to acute effects, late effects, and cosmesis. In the randomized clinical trial of APBI IMRT, the Clinical Target Volume (CTV) was defined by the injection of individual fiducial markers bordering the surgical cavity. We have used the Biozorb fiducial system to localize the CTV for IMRT. We sought to confirm the APBI IMRT results with this simpler less labor intensive fiducial placement system. Methods: Between 2017 and 2021, 214 patients have undergone IMRT targeted to a Biozorb defined CTV with the walls of the surgical cavity sewn to the Biozorb device. Eligible patients were older than age 40, had tumor sizes < 3 cm, negative surgical margins, and negative sentinel node dissections. IMRT dose was 30 Gy given in 5 fractions. Dose Constraints were as follows : V-30 Gy < 105%, Ipsilateral Breast V-15 Gy < 50%, Ipsilateral Lung V-10 Gy < 20%, Contralateral Lung V-5 Gy < 10%, Heart V-3 Gy < 20%, Contralateral Breast Dmax < 2 Gy and Skin Dmax < 27 Gy. The Planning Target Volume (PTV) ranged from 27 to 355 cc with a median of 80 cc. PTV = CTV + 1-2 cm. Results: Follow-up ranged from 1-39 months with a median of 20 months. LR has been 0% (0/214). There have been no skin reactions or seromas. Infection has occurred in one patient (0.5%). Four (1.9%) patients developed pain around the Biozorb site. This resolved on a short courses of steroids in all cases. Cosmetic results as rated by the Surgeon, Radiation Oncologist, and Nurse, were rated excellent in 99.0% (212/214) of cases. Conclusions: Non-invasive APBI with IMRT given qd over 5 days targeted to Biozorb has resulted in LR, complications, and cosmetic results which compare favorably to invasive APBI given bid with HDR implant. At last follow-up, there have been no LR, skin reactions, or significant complications. Cosmesis has been excellent in 99.0% of patients.

Sign in / Sign up

Export Citation Format

Share Document